EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against pox viruses, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against coronaviridae such as SARS-CoV-1. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against pox viruses, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against coronaviridae such as SARS-CoV-1. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases. (en)
|
differentFrom
| |
foaf:name
| |
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
c
| |
CAS number
| |
ChemSpiderID
| |
drug name
| |
H
| |
IUPAC name
| |
legal US
| - Investigational New Drug (en)
|
molecular weight
| |
n
| |
O
| |
PubChem
| |
SMILES
| - NCc1ncnC2[C@H][C@H][C@H]CO (en)
|
StdInChI
| |
StdInChIKey
| - SWQQELWGJDXCFT-ABHRNEANSA-N (en)
|
synonyms
| |
has abstract
| - EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against pox viruses, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against coronaviridae such as SARS-CoV-1. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases. (en)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
CAS number
| |
PubChem
| |
foaf:isPrimaryTopicOf
| |
is differentFrom
of | |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage disambiguates
of | |
is foaf:primaryTopic
of | |